Early Administration of Anti–SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients

Juliette Gueguen1, Charlotte Colosio2, Arnaud Del Bello3, Anne Scemla4, Yohan N’Guyen5, Claire Rouzaud6, Claudia Carvalho-Schneider7, Gabriela Gautier Vargas8, Pierre Tremolières9, A. Jalal Eddine10, Christophe Masset11, Olivier Thaunat12, Melchior Chabannes13, Paulo Malvezzi14, Pierre Pommerolle15, Lionel Couzi16, Nassim Kamar3, Sophie Caillard8 and Philippe Gatault1

1Service de Néphrologie-Hypertension Arterielle, Dialyses, Transplantation Reneale, CHRU de Tours, Tours, France; 2Service de Transplantation Reneale, HOP Robert Debre, Reims, France; 3Department of Nephrology and Organ Transplantation, Toulouse Rangueil University Hospital, Toulouse, France; 4Departement de Nephrologie et Transplantation Reneale, Hopital Necker Enfants Malades, Assistance Publique-Hopitaux de Paris, Paris, France; 5Service de Medecine Interne, Maladies Infectieuses et Immunologie Clinique, Hopital Robert Debre, Reims, France; 6Service de Medecine Infectieuse, Hopital Necker Enfants Malades, Assistance Publique-Hopitaux de Paris, Paris, France; 7Service de Nephrologie and Transplantation, Strasbourg University Hospital, Strasbourg, France; 8Service de Transplantation Reneale, CHU Montpellier, Montpellier, France; 9Service de Transplantation Reneale, Hopitaux Civils, Lyon, France; 10Service de Nephrologie, Dialyse et Transplantation, CHU Besancon, Besancon, France; 11Institut de Transplantation Urologie Nephrologie (ITUN), CHU Nantes, Nantes, France; 12Service de Transplantation Reneale, HOPitaux Civils, Lyon, France; 13Service de Nephrologie, Dialyse, Aphereses et Transplantation Reneale, CHU Grenoble-Alpes, Grenoble, France; 14Service de Nephrologie et Transplantation Reneale, CHU Amiens Sud, Amiens, France; and 15Department of Nephrology, Transplantation, Dialysis and Apheresis, CHU Bordeaux, Bordeaux, France

Introduction: Kidney transplant recipients (KTRs) are prone to develop severe COVID-19 and are less well protected by vaccine than immunocompetent subjects. Thus, the use of neutralizing anti–SARS-CoV-2 monoclonal antibody (MoAb) to confer a passive immunity appears attractive in KTRs.

Methods: We performed a French nationwide study to compare COVID-19–related hospitalization, 30-day admission to intensive care unit (ICU), and 30-day death between KTRs who received an early infusion of MoAb (MoAb group) and KTRs who did not (control group). Controls were identified from the COVID-SFT registry (NCT04360707) using a propensity score matching with the following covariates: age, sex, delay between transplantation and infection, induction and maintenance immunosuppressive therapy, initial symptoms, and comorbidities.

Results: A total of 80 KTRs received MoAb between February 2021 and June 2021. They were matched to 155 controls. COVID-19–related hospitalization, 30-day admission to ICU, and 30-day death between KTRs who received an early infusion of MoAb (MoAb group) and KTRs who did not (control group). Controls were identified from the COVID-SFT registry (NCT04360707) using a propensity score matching with the following covariates: age, sex, delay between transplantation and infection, induction and maintenance immunosuppressive therapy, initial symptoms, and comorbidities.

Conclusion: The early use of MoAb in KTRs with a mild form of COVID-19 largely improved outcomes in KTRs.

Kidney Int Rep (2022) 7, 1241–1247; https://doi.org/10.1016/j.ekir.2022.03.020
KEYWORDS: COVID-19; monoclonal antibody; transplantation; viral infection
© 2022 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

The high frequency of severe comorbidities in KTRs makes them very likely to develop severe COVID-19 caused by SARS-CoV-2.1–3 In addition, their immunization rates after vaccination are lower than in immunocompetent subjects after 1, 2, and even 3 injections of vaccines, with often a low level of anti–SARS-CoV-2 spike protein antibodies.4,5 Thus, a large proportion of KTRs remains currently exposed to the risk of severe COVID-19 despite vaccination.6 In this context, the use of neutralizing anti–SARS-CoV-2 MoAb to confer a passive immunity appears attractive in these patients.
Two large clinical trials have been conducted in high-risk outpatients with recent mild-to-moderate COVID-19. On the basis of a similar virologic primary outcome, both studies demonstrated that monoclonal therapeutic antibodies targeting receptor-binding domain accelerated the viral load decline. In addition, these 2 trials suggested that combinations of bamlanivimab-etesevimab and casirivimab-imdevimab would reduce the proportion of patients requiring further hospitalizations or visits for worsening COVID-19. Finally, US Food and Drug Administration and then European Medicines Agency delivered an emergency use authorization for those therapeutic antibodies in patients at risk of severe COVID-19, including KTRs.

So far, data about the use of these MoAbs in KTRs remain limited. Two small case series reported a good tolerance profile and a low rate of COVID-19–related hospitalization after an early infusion of bamlanivimab. Similar results were obtained in 25 solid organ transplant (SOT) recipients treated with casirivimab-imdevimab. Finally, Del Bello et al. compared 16 SOT recipients who received different MoAbs to 32 nonmatched hospitalized patients and found that neutralizing anti–SARS-CoV-2 MoAbs could prevent acute respiratory failure.

To investigate the efficacy of anti–SARS-CoV-2 MoAb to prevent severe COVID-19 in KTRs, we conducted a nationwide case-control study comparing outcomes between all KTRs in France who had received MoAb between March 2021 and June 15, 2021, in France and matched KTRs issued from the French SOT COVID registry using the propensity score matching method. We compared their risk of COVID-19–related hospitalization, ICU admission, and death.

**METHODS**

**Patients**

In France, the use of MoAb binding the SARS-CoV-2 spike protein was approved on February 2, 2021, for SARS-CoV-2–infected immunosuppressed patients. Eligibility criteria for MoAb infusion were as follows: (i) positive result of reverse transcriptase–polymerase chain reaction test performed on nasopharyngeal swab specimens; (ii) recent symptoms (≤5 days); and (iii) no need of oxygen. We included all KTRs who received MoAb between February and June 15, 2021, in France.

Control group was issued from the French SOT COVID registry (NCT04360707, ethical approval by the Institutional Review Board of the Strasbourg University) that enrolled 1567 KTRs from 31 centers who have COVID-19 until December 31, 2020. The patients with missing data for 1 of the variables needed for matching (n = 377) and those with a negative real-time polymerase chain reaction test result (n = 96) were excluded from the study (Figure 1).

**Data**

Data were collected retrospectively using hospital databases and clinical records for all patients. Each medical record was individually and manually reviewed by a medical doctor in each center. Data collection included patient (age, sex, smoking status, comorbidities: diabetes mellitus, body mass index, hypertension, cardiopathy, chronic lung disease, kidney function) and transplant (induction and maintenance immunosuppressive therapy, donor type, rank) characteristics and COVID-19 characteristics and outcomes (delay between transplantation and COVID-19, symptoms, hospitalization, ICU admission, death).

**Outcomes**

Primary analyses included COVID-19–related hospitalization, ICU admission, and death rates for the first 30 days after the diagnosis. COVID-19–related hospitalization was defined as hospitalization needed because of the severity of the symptoms. For this reason, we did not consider hospitalization for MoAb infusion (as

---

**Figure 1.** Flowchart. KTR, kidney transplant recipient; MoAb, monoclonal antibody; rt-PCR, real-time polymerase chain reaction.
initially recommended by the French authorities) and nosocomial COVID-19 if patients did not show any exacerbation during hospitalization. We secondarily analyzed rate of severe COVID-19 defined as admission (or transfer) to ICU, need for mechanical ventilation, or death. We finally provided 3-month patient survival defined as the time between the date of positive real-time polymerase chain reaction test and the date of death or last follow-up.

Propensity Score Matching
KTRs in the MoAb group were matched to KTRs issued from COVID-SFT registry by a propensity score, using a 1:2 ratio, nearest neighbor method, and a caliper of 0.3 with the following covariates: age, sex, time between transplant and positive SARS-CoV-2 real-time polymerase chain reaction test result, induction therapy, maintenance immunosuppression; body mass index, diabetes mellitus, history of cardiovascular disease, hypertension, chronic lung disease and creatinine, fever and dyspnea at time of MoAb infusion (or COVID-19 diagnosis). The balance of covariate distribution between the 2 groups was assessed using standardized mean differences (Supplementary Data).

Missing Data
Propensity score matching method requires fully completed data. To keep all KTRs included in the study, we imputed the few missing data in the MoAb group as follows: 3 data were missing for induction and were imputed by “basiliximab” to allow matching with basiliximab-treated controls to favor the control group; 1 data were missing for body mass index and imputed using the median of body mass index for the same age and sex. Patients with missing data in the control group were excluded before matching.

Statistical Analysis
Continuous variables were described using medians and interquartile ranges and compared using the Mann-Whitney rank-sum test. Categorical variables were described using proportions and compared using Fisher exact test. Survivals were represented using Kaplan–Meier curves and compared using a 2-sided log-rank test. Statistical analyses were performed using Stata (StataCorp College Station, TX) and R Studio (RStudio, version 1.2.1335). All statistical tests were 2-sided, and \( P < 0.05 \) was considered as significant.

RESULTS
Patient Characteristics
Overall, 80 KTRs from 13 transplant centers received MoAb. They were initially treated with bamlanivimab \((n = 8)\) and then with bamlanivimab-etesevimab \((n = 39)\) or casirivimab-imdevimab \((n = 33)\) (Figure 2). The mean delay between the first symptoms and the administration of MoAb was \(3.8 \pm 2.4\) days with 6 patients treated beyond the fifth day.

The matching process identified 155 control patients among 1094 patients included from the COVID-SFT registry. Their basal characteristics were compared with those of patients treated with MoAb (Table 1). As expected, no significant differences were observed regarding age, immunosuppressive regimen, delay of transplantation, and comorbidities. Of note, the proportion of asymptomatic KTRs was lower in the MoAb group than in the control group \((1.3\% \text{ vs. } 21.3\%, P < 0.001)\).

Regarding immunosuppressive therapy management after diagnosis of COVID-19, we found that a slight
Table 1. Patient characteristics

| Variable                              | MoAb group (n = 80) | Control group (n = 155) | P value |
|---------------------------------------|---------------------|-------------------------|---------|
| Male sex, n (%)                       | 45 (56.3)           | 90 (58)                 | 0.889   |
| Age, median (IQR)                     | 57 (46–64.5)        | 57 (44–66.5)            | 0.940   |
| Age > 60 yr, n (%)                    | 34 (43)             | 65 (42)                 | 0.999   |
| BMI (kg/m²), median (IQR)             | 26.1 (23.7–30.1)    | 27 (23.4–30)            | 0.952   |
| Time from transplantation to COVID-19 (mo), median (IQR) | 57 (17–139) | 64 (21–140) | 0.521 |
| COVID-19 during the first post-transplant yr, n (%) | 15 (18.8) | 26 (16.8) | 0.719 |
| First transplantation, n (%)          | 67 (83.8)           | 142 (91.6)              | 0.081   |
| Combined transplantation, n (%)       | 4 (5)               | 6 (3.9)                 | 0.999   |
| Living donor, n (%)                   | 15 (18.8)           | 23 (14.8)               | 0.458   |
| T-cell depletion, n (%)               | 42 (52.5)           | 87 (56.1)               | 0.776   |
| Comorbidities, n (%)                  |                     |                         |         |
| Diabetes mellitus                     | 27 (33.8)           | 50 (32.3)               | 0.884   |
| Cardiac disease                       | 21 (26.3)           | 38 (24.5)               | 0.874   |
| Hypertension                          | 62 (77.5)           | 127 (81.9)              | 0.488   |
| Cancer                                | 10 (12.5)           | 26 (16.8)               | 0.448   |
| Respiratory disease                   | 11 (13.8)           | 24 (15.5)               | 0.847   |
| BMI ≥ 30 kg/m²                        | 20 (25)             | 42 (27.1)               | 0.757   |
| Number                                | 1.9 ± 1.3           | 2.0 ± 1.2               | 0.688   |
| Tobacco use, n (%)                    | 8 (10)              | 18 (11.6)               | 0.423   |
| Symptoms, n (%)                       |                     |                         |         |
| None                                  | 1 (1.3)             | 31 (21.3)               | <0.001  |
| Dyspnea                               | 11 (13.8)           | 28 (18.1)               | 0.462   |
| Fever                                 | 34 (42.5)           | 57 (36.8)               | 0.400   |
| Headache                              | 22 (27.5)           | 29 (18.7)               | 0.135   |
| Myalgia                               | 26 (32.5)           | 28 (18.9)               | 0.033   |
| Cough                                 | 45 (56.3)           | 70 (45.2)               | 0.130   |
| Diarrhea                              | 20 (25)             | 45 (29)                 | 0.542   |
| Vomiting                              | 3 (3.8)             | 9 (6.2)                 | 0.546   |
| Immunosuppression, n (%)              |                     |                         |         |
| Calciuminuria inhibitor               | 71 (88.8)           | 141 (91)                | 0.645   |
| Mycophenolic acid                     | 60 (75)             | 110 (71)                | 0.542   |
| Azathioprine                          | 4 (5)               | 13 (8.4)                | 0.432   |
| mTOR inhibitor                        | 13 (16.3)           | 26 (16.8)               | 0.999   |
| Belatacept                            | 4 (5)               | 3 (1.9)                 | 0.233   |
| Steroids                              | 62 (77.5)           | 119 (76.8)              | 0.999   |
| Suspension of immunosuppression, n (%)|                     |                         |         |
| Calciuminuria inhibitor               | 4 (5.6)             | 18 (13.5)               | 0.083   |
| Mycophenolic acid/azathioprine        | 27 (34.2)           | 47 (38.2)               | 0.598   |
| mTOR inhibitor                        | 6 (7.5)             | 14 (9.9)                | 0.651   |
| Vaccinated                            | 33 (44.2)           | 0 (0.0)                 | <0.0001 |
| Creatinine level at baseline before COVID-19 (µmol/l), med (IQR) | 125 (100–165) | 130 (100–174) | 0.699 |

BMI, body mass index, IQR, interquartile range, MoAb, monoclonal antibody; mTOR, mammalian target of rapamycin. Bold data indicate significant difference.

Most of KTRs (n = 126, 53.6%) underwent a reduction of their immunosuppression (MoAb: 39 [48.8%] vs. controls: 87 [58.0%], P = 0.179). In detail, clinicians suspended mycophenolic acid, calciuminuric inhibitor, or mammalian target of rapamycin inhibitors in 39.6%, 10.8%, and 51.3% of patients in similar proportion in both groups. Treatment with belatacept was maintained in all treated KTRs (n = 7).

Finally, the unique clinically relevant difference between the groups concerned vaccination. Indeed, because vaccination was not yet available in 2020, no patient in the control group was vaccinated. In contrast, 33 KTRs (44.2%) treated with MoAb had received at least 1 dose of vaccine (1 dose: 17, 2 doses: 19, 3 doses: 3). Antispike protein antibodies before MoAb injection were detected in only 10 patients.

Patient Outcomes

In the first month, KTRs were less frequently hospitalized for worsening COVID-19 in the MoAb group than in the control group (28 [35.0%] vs. 77 [49.7%], P = 0.032). Of note, 15 of 28 patients (53.6%) were vaccinated (1 dose: 8, 2 doses: 6, 3 doses: 1), 3 of whom had detectable antispike antibodies before injection of MoAb. Likewise, we observed a lower proportion of patients admitted to the ICU in the MoAb group (2 [2.5%] vs. 24 [15.5%], P = 0.002). Both patients admitted to the ICU in the MoAb group never required mechanical ventilation (Table 2).

Only 1 death (1.25%) occurred after administration of MoAb. It happened in a 76-year-old male patient with numerous comorbidities and advanced vascular dementia disqualified for ICU admission. COVID-19 was diagnosed 10 years after the transplantation while the patient had already been hospitalized for confusion (SARS-CoV-2 negative result on admission) in the context of a cluster recently developed in the unit. The early injection of a bamlanivimab-etesevimab combination 1 day after the first symptoms did not prevent the worsening of COVID-19 with a severe respiratory disease leading to death 5 days later.

The mortality in the control group was higher with 21 deaths (13.6%) notified during the follow-up (Figure 3). Of 21 deaths, 18 (85.7%) occurred in the first month. The 30-day mortality rate was lower in the MoAb group (P = 0.008), as shown in Table 2. On the basis of an absolute risk reduction of 10.35%, we estimated that 9.7 patients should be treated to avoid 1 death.

DISCUSSION

In this carefully designed, multicenter, case-control study, we investigated the effectiveness of early infusion of neutralizing MoAb in the treatment of mild or

Table 2. Comparison of outcomes at 1 month of kidney transplant recipients treated or not with anti-SARS-CoV-2 antibodies

| Outcomes                        | MoAb group (n = 80) | Control group (n = 155) | P value |
|---------------------------------|--------------------|-------------------------|---------|
| Severe COVID-19, n (%)          | 3 (3.8)            | 30 (19.4)               | 0.001   |
| Admission to ICU, n (%)         | 2 (2.5)            | 24 (15.5)               | 0.002   |
| Need for mechanical ventilation, n (%) | 0 (0.0)   | 18 (11.6)               | <0.001  |
| Death, n (%)                    | 1 (1.25)           | 18 (11.6)               | 0.005   |

ICU, intensive care unit.
moderate COVID-19 in KTRs. We demonstrate that an early infusion of MoAb reduces the risk of severe COVID-19 with a 10-fold lower risk of admission to ICUs and death and, therefore, strongly comforts preliminary results reported in SOT recipients without major side effects.11–13

This remarkable effectiveness of MoAb is the result of the strong potency of antispikes MoAb to limit the spread of the virus at the first stage of the infection. As most of the neutralizing antibodies in SARS-CoV-2–infected patients which contribute to the protection of the patients, currently available MoAbs recognize the receptor-binding domain located on the S1 subunit of viral spike, which is the main antigenic domain with the N-terminal domain.14 Because these domains are less conserved than other parts of the spike protein, SARS-CoV-2 variants can escape to MoAb neutralization.15,16 It occurred for bamlanivimab unable to neutralize the now dominant SARS-CoV-2 variant B.1.617 and therefore revoked as monotherapy. In our study, patients in the MoAb group were mostly exposed to B.1.1.7 variant considered as more pathogenic than ancestor Wuhan strain still dominant when control patients were infected, because the period of enrollment differed between the 2 groups.17,18 Although MoAb could be more broadly used as preventive therapy in nonresponder to vaccination or in prolonged COVID-19,19,20 it is important to keep in mind that effectiveness of these treatment must regularly be updated21 and therapeutic strategies potentially refined taking account the geographic distribution of different SARS-CoV-2 strains. The last illustration is the recent propagation of the Omicron variant that escapes to casirivimab and imdevimab. The use of antibodies that target highly conserved epitopes, such as sotrovimab, could represent an attractive alternative.22–24

It is important to consider the efficacy of MoAb in light of risk profile of the population. The 2 first sponsored clinical trials were conducted in immunocompetent patients supposed to be at high risk of worsening COVID-19. The clinical benefit observed in patients treated with bamlanivimab-etesevimab and casirivimab-imdevimab remained uncertain because of the unexpected low number of hospitalization.7,9 Several observational studies brought more convincing results with a lower risk of hospitalization in patients treated with MoAb.25,26 However, one of the studies that compared 594 patients with 5536 unmatched contemporaneous patients and 7404 historical patients failed to show a clear effect on mortality.26 This was likely due to the short follow-up (14 days) and again the fairly low risk of death in control patients (1%). In our study, 11.6% of matched KTRs passed away during the first month, close to the proportion found in a well-designed case-control study that found a strong reduction of mortality using MoAb (0% vs. 9.4%).25 It is of note that real-life studies that included a large number of immunocompromised patients unfortunately did not discriminate SOT from other causes of immunosuppression (hematopoietic stem cell transplant recipient, HIV, or currently

Figure 3. The 90-day patient survival in the patients treated with an early injection of anti–SARS-CoV-2 therapeutic antibody was greater than and matched than that of control recipients. Patients treated with therapeutic antibodies and control patients are presented by continuous and dotted line, respectively. The survival was higher in the patients treated with monoclonal antibodies (log-rank, \( P = 0.004 \)). MoAb, monoclonal antibody.
receiving chemotherapy) and did not specifically investigate the efficacy of MoAb in immunocompromised patients.26,27 Finally, we can conclude that immunosuppression confers a high risk of worsening COVID-19 but does not alter the efficacy of MoAb.

Today, the first-line weapon against COVID-19 is obviously vaccines, especially mRNA-based vaccines.28–30 Nowadays, it is clear that immune response to COVID-19 vaccination is affected by immunosuppressive drugs. Indeed, although mRNA-based vaccine elicits antibody response in >95% in general population, the proportion of SOT recipients who developed antispike protein after 1 dose is meager, estimated between 5% and 17%.4,31,32 Second and third injections increase the proportion of SOT recipients with antispike protein antibodies to approximately 40% and 70%,12–34 but not in KTRs treated with belatacept who keep a very weak immune response.35 In our study, only 10 patients (12.5%) were sensitized before infusion of MoAb. In our opinion, a positive impact of vaccination cannot be considered as sufficient to explain the drastic reduction of worsening COVID-19 in KTRs treated with MoAb, even though complementary data about neutralizing antibodies would have been of interest. Because the positive effect of MoAb is restricted to seronegative patients,7 a systematic quantification of antispike or anti-RBD antibodies after the third dose or the booster dose should be recommended to select patients who would benefit an early MoAb injection. Our study in addition underscores that caregivers should provide consistent information about the importance to promptly diagnose COVID-19 if they face any suggestive symptoms.

In conclusion, the early use of MoAb in KTRs with a mild form of COVID-19 dramatically improves outcome of KTRs. Our results highlight the importance of a prompt diagnosis after first symptoms (or exposure to the virus) among SOT recipients who are frequently nonresponders to vaccines, alongside the maintenance of nonmedical preventive measures.

**DISCLOSURE**

All the authors declared no competing interests.

**ACKNOWLEDGMENTS**

The authors thank all participants who contributed to the French SOT COVID Registry: Hélène Francois, Marie Matignon, Clarisse Greze, Tristan Legris, Luc Frimat, Renaud Snaouad, Antoine Sicard, Dominique Bertrand, Christiane Mousson, Antoine Thierry, Jonathan M. Chemouny, Agnes Duveau, Valérie Moal, Philippe Grimbert, Yannick LeMeur, and Marc Hazan.

**SUPPLEMENTARY MATERIAL**

Supplementary File (PDF)

Loveplot for balance of covariances between KTRs in MoAb group and control group before and after adjustment.

**STROBE statement.**

**REFERENCES**

1. Caillard S, Anglicheau D, Matignon M, et al. An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. *Kidney Int*. 2020;98:1549–1558. https://doi.org/10.1016/j.kint.2020.08.005

2. Caillard S, Chavarot N, Francois H, et al. Is COVID-19 infection more severe in kidney transplant recipients? *Am J Transplant*. 2021;21:1295–1303. https://doi.org/10.1111/ajt.16424

3. Chavarot N, Gueguen J, Bonnet G, et al. COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities. *Am J Transplant*. 2021;21:1285–1294. https://doi.org/10.1111/ajt.16416

4. Boyarsky BJ, Werbel WA, Avery RK, et al. Immuno­genicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. *JAMA*. 2021;325:1784–1786. https://doi.org/10.1001/jama.2021.4385

5. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients. *N Engl J Med*. 2021;385:661–662. https://doi.org/10.1056/NEJMct2108861

6. Caillard S, Chavarot N, Bertrand D, et al. Occurrence of severe COVID-19 in vaccinated transplant patients. *Kidney Int*. 2021;100:477–479. https://doi.org/10.1016/j.kint.2021.05.011

7. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COVID, a neutralizing antibody cocktail, in outpatients with COVID-19. *N Engl J Med*. 2021;384:238–251. https://doi.org/10.1056/NEJMoa2035002

8. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. *N Engl J Med*. 2021;384:229–237. https://doi.org/10.1056/NEJMoa2029849

9. Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. *JAMA*. 2021;325:632–644. https://doi.org/10.1001/jama.2021.0202

10. Dhand A, Lobo SA, Wolfe K, Feola N, Nabors C. Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: early single-center experience. *Clin Transpl*. 2021:e14245. https://doi.org/10.1111/crt.14245

11. Kutzler HL, Kuzaro HA, Serrano OK, Feingold A, Morgan G, Cheema F. Initial experience of bamlanivimab monotherapy use in solid organ transplant recipients. *Transplant Infect Dis*. 2021:e13662. https://doi.org/10.1111/tid.13662

12. Dhand A, Lobo SA, Wolfe K, et al. Casirivimab-Imdevimab for treatment of COVID-19 in solid organ transplant recipients: an early experience. *Transplantation*. 2021;105:e68–e69. https://doi.org/10.1097/TP.0000000000003737

13. Del Bello A, Marion O, Vellas C, et al. Anti-SARS-CoV-2 monoclonal antibodies in solid-organ-transplant patients.
24. Pinto D, Park YJ, Beltramello M, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature*. 2020;583:290–295. https://doi.org/10.1038/s41586-020-2349-y

25. Destache CJ, Aurit SJ, Schmidt D, Peet Erkes L, Tierney M, Vivekanandan R. Bamlanivimab use in mild-to-moderate COVID-19 disease: a matched cohort design. *Pharmacotherapy*. 2021;41:743–747. https://doi.org/10.1002/pha.2613

26. Webb BJ, Buckel W, Vento T, et al. Real-world effectiveness and tolerability of monoclonal antibody therapy for ambulatory patients with early COVID-19. *Open Forum Infect Dis*. 2021;8:ofab331. https://doi.org/10.1093/ofid/ofab331

27. Ganesh R, Philpot LM, Bierle DM, et al. Real-world clinical outcomes of bamlanivimab and casirivimab-imbudimab among high-risk patients with mild to moderate coronavirus disease 2019. *J Infect Dis*. 2021;224:1278–1286. https://doi.org/10.1093/infdis/jjab377

28. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med*. 2021;384:403–416. https://doi.org/10.1056/NEJMoa2035389

29. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. *N Engl J Med*. 2020;383:2603–2615. https://doi.org/10.1056/NEJMoa2034577

30. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. *N Engl J Med*. 2021;384:1412–1423. https://doi.org/10.1056/NEJMoa2101765

31. Benotmane I, Gautier-Vargas G, Cognard N, et al. Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. *Kidney Int*. 2021;99:1487–1489. https://doi.org/10.1016/j.kint.2021.03.014

32. Del Bello A, Abravanel F, Marion O, et al. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. *Am J Transplant*. 2022;22:322–323. https://doi.org/10.1111/ajt.16775

33. Hall VG, Ferreira VH, Ku T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. *N Engl J Med*. 2021;385:1244–1246. https://doi.org/10.1056/NEJMct2111462

34. Marlet J, Gatault P, Maakaroun Z, et al. Antibody responses after a third dose of COVID-19 vaccine in kidney transplant recipients and patients treated for chronic lymphocytic leukemia. *Vaccines (Basel)*. 2021;9:1056. https://doi.org/10.3390/vaccines9101055

35. Chavarot N, Morel A, Leruez-Ville M, et al. Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept. *Am J Transplant*. 2021;21:4043–4051. https://doi.org/10.1111/ajt.16814